Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Assura considering PHP bid, postpones shareholder vote

(Sharecast News) - Healthcare property investment and management firm Assura has delayed an upcoming shareholder vote on the takeover proposal from KKR and Stonepeak as it assesses a competing proposal from Primary Health Properties. Assura had reached an agreement with KKR and Stonepeak, together known as Sana Bidco, on 9 April regarding a recommended cash offer valuing the company at 49.4p per share.

A meeting was then scheduled for 5 June where shareholders would be required to vote on the offer.

However, on 16 May, PHP re-entered the fray - having had an earlier proposal rejected - with a sweetened bid of 51.7p per share.

As a result, Assura said it has now adjourning next month's meeting after having engaged in further discussions with PHP, and is commencing due diligence to determine whether or not to recommend the PHP offer to shareholders.

"In the context of this continued engagement, the Assura board has decided to adjourn the Court Meeting and the General Meeting required to implement the Cash Offer from Bidco, which are due to be held on 5 June 2025," Assura said.

"It is therefore recommended that Assura Shareholders do not attend the Meetings scheduled for 5 June 2025 and take no further action at this stage in relation to the Cash Offer and the PHP Offer."

Assura shares were flat at 49.12p on Friday morning.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.